Research Guide

Peptide Administration Routes: Bioavailability Guide

Research guide to peptide administration routes — subcutaneous, intramuscular, intranasal, and oral delivery. Bioavailability data, mechanisms, and PubMed-cited evidence for each route.

Last updated Jun 11, 2026 10 min read

The route by which a peptide enters the body is not a secondary consideration — it is a fundamental determinant of whether the compound reaches its target tissue in sufficient concentration to produce a measurable biological effect. A peptide that shows dramatic activity in cell culture may fail entirely when administered orally, simply because gastrointestinal enzymes degrade it before absorption occurs. The same peptide administered subcutaneously might show robust effects, because it bypasses the GI tract entirely and enters the bloodstream through capillary absorption in the dermal tissue.

This guide examines the four primary administration routes that researchers have explored for peptide compounds: subcutaneous injection (SC), intramuscular injection (IM), intranasal delivery, and oral administration. Each route presents distinct pharmacokinetic characteristics — different absorption rates, different bioavailability profiles, and different practical considerations for research protocols.

Understanding these differences is essential for interpreting preclinical data accurately. A study that reports positive effects using intraperitoneal injection in rodents does not necessarily predict equivalent results with subcutaneous administration in a different model. The route, the volume, the concentration, and the formulation all influence the pharmacokinetic profile — and therefore the biological outcome.

Overview

Subcutaneous injection is the most widely used administration route in peptide research, employed for the majority of compounds discussed on CompoundGuide — from growth hormone secretagogues ( CJC-1295 , Ipamorelin , Sermorelin , Tesamorelin ) to healing peptides ( BPC-157 , TB-500 , GHK-Cu ) and metabolic compounds ( MOTS-c , AOD-9604 , Epitalon ). It offers reliable absorption through the vascularized subcutaneous tissue, with a relatively slow and sustained release profile compared to intravenous administration.

Intramuscular injection is used for specific compounds where faster absorption or higher volume tolerance is desired. The rich vascular supply of skeletal muscle produces faster peak plasma levels than subcutaneous tissue, though for most peptides the practical difference is modest.

Intranasal delivery represents a fundamentally different approach — bypassing systemic circulation entirely to target the central nervous system directly. The nasal mucosa provides a unique anatomical pathway to the brain via the olfactory and trigeminal nerve routes, making this route particularly relevant for neuropeptides like Semax and Selank .

Oral administration is the most convenient route theoretically but the most challenging for peptides. The combination of gastric acid, proteolytic enzymes (pepsin, trypsin, chymotrypsin), and the intestinal epithelial barrier creates a hostile environment that degrades most peptide compounds before they can be absorbed. A few peptides — notably BPC-157 — have shown unexpected oral bioactivity in preclinical research, a finding that has attracted significant scientific interest.

Compounds in This Guide

BPC-157

Gastrointestinal protection & systemic tissue repair

Full profile â†’

Subcutaneous injection is the most studied administration route for BPC-157 in preclinical research, and it serves as the reference method for understanding this peptide's pharmacokinetic behavior. When injected into the subcutaneous tissue of the abdominal wall or lateral thigh — the two most common sites in research protocols — BPC-157 is absorbed through the capillary network in the dermis and enters the systemic circulation.

The subcutaneous route offers several practical advantages for peptide research: injection volumes are typically 0.1–0.5 mL, which is well within the tissue's capacity; the absorption rate is slower and more sustained than intravenous administration, reducing the need for frequent dosing; and the technique is straightforward, requiring only a short (29–31 gauge) needle and basic aseptic technique.

BPC-157 has also been studied via intramuscular injection in several preclinical models, where it showed comparable biological activity to subcutaneous administration. The choice between SC and IM in research settings often depends on the specific study design rather than meaningful differences in BPC-157's bioavailability through either route.

What distinguishes BPC-157 from most other research peptides is its documented oral bioactivity . Multiple preclinical studies have reported biological effects when BPC-157 was administered orally — a finding that is mechanistically surprising for a 15-amino-acid peptide, since most peptides of this size are expected to be substantially degraded by gastric and intestinal proteases before reaching the systemic circulation. The proposed explanation relates to BPC-157's gastric origin: as a peptide derived from a gastric juice protein, it may possess inherent resistance to the very digestive enzymes found in the stomach environment. This oral bioactivity has made BPC-157 one of the few peptides where researchers actively study oral delivery as a viable research route.

gut-healing tendon-repair wound-healing injury-recovery

TB-500

Systemic tissue repair & angiogenesis

Full profile â†’

Intramuscular injection is a well-characterized route for TB-500 ( Thymosin Beta-4 fragment) in preclinical research, used alongside subcutaneous injection in many study protocols. The choice of IM over SC for TB-500 is often driven by the specific experimental context rather than a clear pharmacokinetic advantage.

Skeletal muscle tissue has a denser capillary network than subcutaneous fat, which theoretically produces faster absorption and higher initial peak plasma concentrations. For TB-500 , this difference is particularly relevant in studies examining muscle repair — injecting the peptide directly into or near the target tissue creates a local concentration gradient that may influence the early phases of the healing response. Researchers studying TB-500's effects on skeletal muscle injury have used both intramuscular injection at the injury site and systemic subcutaneous injection to compare local versus systemic delivery effects.

TB-500 has also been administered subcutaneously in studies examining its systemic effects on wound healing, angiogenesis, and anti-inflammatory activity. Because TB-500's mechanism involves actin regulation — a universal intracellular process — its effects are inherently systemic regardless of the injection route, which may reduce the pharmacokinetic significance of route selection compared to peptides that act on tissue-specific receptors.

The parent compound Thymosin Beta-4 has progressed further in clinical research than most peptides discussed on CompoundGuide, with Phase I and Phase II clinical trials in specific therapeutic contexts. These clinical studies have primarily used intravenous or subcutaneous administration, providing some human pharmacokinetic data for the compound class.

wound-healing tendon-repair injury-recovery

GHK-Cu

Skin regeneration & collagen synthesis

Full profile â†’

skin-health wound-healing anti-aging

CJC-1295

Growth hormone-releasing hormone analogue

Full profile â†’

muscle-growth fat-loss anti-aging

Ipamorelin

Selective growth hormone secretagogue

Full profile â†’

muscle-growth fat-loss sleep

Sermorelin

GHRH analog for endogenous growth hormone stimulation

Full profile â†’

growth-hormone-deficiency body-composition skin-health sleep-quality

Tesamorelin

GHRH analogue studied for visceral fat reduction and GH-axis stimulation

Full profile â†’

fat-loss metabolic-health muscle-growth

Semax

ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance

Full profile â†’

Intranasal delivery is the primary researched administration route for Semax , and it illustrates a pharmacokinetic principle that distinguishes neuropeptides from systemic peptides: the ability to bypass the blood-brain barrier entirely.

The nasal mucosa — particularly the olfactory epithelium in the upper nasal cavity — provides a unique anatomical pathway to the central nervous system. Olfactory neurons extend directly from the nasal cavity through the cribriform plate into the brain, creating a potential conduit for molecules that cannot cross the blood-brain barrier through conventional systemic circulation. The trigeminal nerve provides a second pathway, distributing compounds to the brainstem and spinal cord.

For Semax — a synthetic ACTH(4-10) fragment studied for its effects on brain-derived neurotrophic factor (BDNF) expression and cognitive function — intranasal delivery offers a direct route to the brain tissue where its neurotrophic effects are studied. The peptide's short half-life in plasma (minutes) means that systemic circulation would degrade it rapidly; intranasal delivery may allow sufficient CNS concentrations before systemic clearance occurs.

Selank , a related neuropeptide studied for anxiolytic and immunomodulatory effects , is also primarily studied via intranasal administration for the same anatomical reasons. Both compounds have been approved for clinical use in Russia and CIS countries, where they are formulated as intranasal sprays — one of the few examples of peptides where intranasal delivery has progressed beyond preclinical research into actual clinical formulation.

Epitalon , a synthetic tetrapeptide studied for telomerase activation, has also been investigated via intranasal delivery, though subcutaneous injection remains the more commonly reported route in the published literature.

cognitive-enhancement neuroprotection mood-support

Selank

Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response

Full profile â†’

anxiety-reduction immune-modulation cognitive-enhancement

MOTS-c

Mitochondrial-encoded peptide studied for metabolic regulation and longevity

Full profile â†’

metabolic-health anti-aging fat-loss

AOD-9604

Fragment peptide studied for fat metabolism and lipolysis

Full profile â†’

fat-loss metabolic-health

Epitalon

Pineal peptide studied for telomerase activation and longevity

Full profile â†’

anti-aging sleep-quality immune-function skin-health

KPV

Tripeptide fragment studied for anti-inflammatory and gut-barrier effects

Full profile â†’

Oral administration is the most challenging delivery route for peptides, and the reasons are well-characterized biochemically. The gastrointestinal tract is designed to break down proteins and peptides into their constituent amino acids for absorption — a process that is highly efficient and works against the goal of delivering intact peptide molecules to the systemic circulation.

Three barriers must be overcome: gastric acid (pH 1.5–3.5), which denatures most peptide structures; proteolytic enzymes (pepsin in the stomach, trypsin and chymotrypsin in the small intestine), which cleave peptide bonds; and the intestinal epithelial barrier, which limits absorption of molecules larger than approximately 500 daltons through passive diffusion.

For KPV — a tripeptide (Lys-Pro-Val) derived from alpha-MSH — oral delivery is studied specifically because the target tissue is the intestinal epithelium itself. KPV's research focus on intestinal barrier integrity and local anti-inflammatory effects means the peptide does not necessarily need to survive intact absorption into systemic circulation; local activity within the gut lumen may be sufficient. This makes oral delivery a mechanistically rational choice for KPV rather than a pharmacokinetic compromise.

BPC-157 , despite being a larger 15-amino-acid peptide, has shown surprising oral bioactivity in preclinical studies . AOD-9604 has also been studied via oral administration, though the published evidence is more limited. For the vast majority of research peptides — including the growth hormone secretagogues ( CJC-1295 , Ipamorelin , Sermorelin , Tesamorelin ), the healing peptides ( TB-500 , GHK-Cu ), and the metabolic peptides ( MOTS-c , Epitalon ) — oral administration is not a viable research route due to rapid enzymatic degradation. This is why subcutaneous injection remains the dominant delivery method across peptide research.

anti-inflammatory gut-healing

How They Work Together

Route Selection as a Research Variable

The choice of administration route is not merely a practical convenience — it is an experimental variable that influences the pharmacokinetic profile, tissue distribution, and potentially the biological outcome of any peptide study. Researchers must consider the peptide's molecular properties (size, charge, stability), the target tissue (systemic vs. local vs. CNS), and the specific research question when selecting a delivery route.

For systemic effects — growth hormone modulation, metabolic regulation, wound healing — subcutaneous injection is the default choice because it provides reliable absorption with a sustained release profile. Intramuscular injection is used when faster initial absorption is desired or when the injection site itself is the target tissue.

For central nervous system effects — cognitive enhancement, neuroprotection, anxiolysis — intranasal delivery offers a pathway that systemic injection cannot replicate. The blood-brain barrier excludes most circulating peptides; intranasal delivery via the olfactory nerve route bypasses this barrier entirely.

For gastrointestinal effects — intestinal barrier integrity, local anti-inflammatory activity in the gut — oral delivery is the logical choice, even though systemic bioavailability through this route is expected to be minimal for most peptides.

Some research protocols use multiple routes in the same study to compare bioavailability and efficacy. This comparative approach — administering the same peptide via different routes in parallel groups — is one of the most informative experimental designs for understanding a compound's pharmacokinetic behavior. The data from such studies inform both the interpretation of existing research and the design of future protocols.

Frequently Asked Questions

: Subcutaneous injection is preferred because it provides reliable absorption through the vascularized subcutaneous tissue with a sustained release profile. It avoids the first-pass metabolism that degrades orally administered peptides and the rapid clearance of intravenous injection. The technique is straightforward, injection volumes are small (0.1–0.5 mL), and the slower absorption reduces peak-trough fluctuations in plasma levels. For most peptides — growth hormone secretagogues, healing peptides, metabolic compounds — subcutaneous administration produces consistent and reproducible pharmacokinetics in preclinical models.
: The primary difference is absorption rate. Intramuscular tissue has a denser capillary network than subcutaneous fat, producing faster initial absorption and higher peak plasma concentrations. For most peptides, this difference is modest and does not significantly alter biological outcomes. The choice between routes in research settings is often determined by the study design: intramuscular injection may be preferred when the muscle itself is the target tissue (e.g., TB-500 for muscle repair) or when larger injection volumes are needed. Subcutaneous injection is preferred for sustained systemic delivery.
: Intranasal delivery exploits the unique anatomy of the nasal mucosa, which provides direct pathways to the brain. The olfactory epithelium in the upper nasal cavity contains neurons that extend through the cribriform plate into the cranial cavity, creating a conduit from the nasal surface to brain tissue. The trigeminal nerve provides a second pathway to the brainstem and spinal cord. For neuropeptides like Semax and Selank, this route bypasses the blood-brain barrier — which normally excludes most circulating peptides — and delivers the compound directly to the central nervous system. This is why both compounds are formulated as intranasal sprays in their approved clinical applications.
: Most peptides cannot be effectively administered orally because the gastrointestinal tract is designed to degrade proteins and peptides. Gastric acid (pH 1.5–3.5) denatures peptide structures, while enzymes like pepsin, trypsin, and chymotrypsin cleave peptide bonds. Additionally, the intestinal epithelium limits absorption of molecules larger than ~500 daltons. However, there are notable exceptions: BPC-157 has shown oral bioactivity in multiple preclinical studies [PMID: 25529739], possibly due to its origin as a gastric juice-derived peptide with inherent resistance to GI enzymes. KPV is studied orally because its target tissue is the intestinal epithelium itself, so local gut activity may be sufficient without systemic absorption.
: Yes, substantially. Bioavailability — the fraction of administered compound that reaches systemic circulation in active form — varies dramatically by route. Intravenous injection provides 100% bioavailability by definition. Subcutaneous injection typically provides moderate to high bioavailability depending on the peptide's stability in tissue. Intranasal bioavailability varies widely depending on mucosal absorption and local enzymatic degradation. Oral bioavailability for most peptides is near zero due to GI degradation. The specific bioavailability values for individual peptides are compound-dependent and must be determined experimentally for each route.
: Reconstituted lyophilized peptides for injection are the standard research format because they provide the most reliable and reproducible delivery. Lyophilization (freeze-drying) preserves peptide stability during storage, and reconstitution with bacteriostatic water or sterile saline immediately before use ensures consistent concentration. Oral formulations face the fundamental challenge of enzymatic degradation — most peptides lose activity during transit through the GI tract. Developing oral peptide formulations that protect against degradation (enteric coatings, nanoparticle encapsulation, permeation enhancers) is an active area of pharmaceutical research, but these technologies are not yet standard in preclinical peptide research.

Summary

Administration route selection is a foundational decision in peptide research that affects every downstream pharmacokinetic parameter — from the rate and extent of absorption to the distribution, metabolism, and duration of biological activity.

Subcutaneous injection remains the workhorse of peptide research, applicable to virtually all compounds and supported by decades of preclinical protocol standardization. Intramuscular injection provides a useful alternative for specific contexts, particularly when local tissue delivery or faster absorption kinetics are desired.

Intranasal delivery represents a specialized but important route for neuropeptides, offering access to the central nervous system through anatomical pathways that systemic injection cannot reach. The clinical translation of Semax and Selank as intranasal formulations demonstrates that this route can move beyond preclinical research into approved therapeutic products.

Oral delivery remains the most challenging route for peptides, with enzymatic degradation and epithelial barriers limiting bioavailability for most compounds. The exceptions — BPC-157 's documented oral bioactivity and KPV 's local gut activity — are scientifically interesting precisely because they deviate from the expected pattern.

For researchers designing peptide studies, the most rigorous approach is to select the administration route based on the compound's known pharmacokinetics, the target tissue, and the specific research question — and to report the route, dose, volume, and formulation in sufficient detail for replication.